AEHL vs GWAV
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
AEHL exhibits weak financial health with a Piotroski F-Score of 4/9, indicating a fragile operational foundation despite some positive earnings surprises. The absence of an Altman Z-Score and persistent negative profitability metrics—particularly a -17.69% profit margin and negative ROE—signal deep structural issues. Although revenue growth is explosive at 101.4% YoY, this is not translating into sustainable earnings or cash flow, and the stock trades at a deeply discounted valuation (Price/Book: 0.08, Price/Sales: 0.04), likely reflecting severe market skepticism. The 52-week price decline of 93% and lack of analyst coverage further underscore investor pessimism. The company remains fundamentally unviable under current conditions.
GWAV exhibits severe financial distress, anchored by a weak Piotroski F-Score of 3/9 and a critical liquidity crisis. While the company shows strong top-line revenue growth of 49%, this is completely offset by a catastrophic profit margin of -84.21% and a Current Ratio of 0.34, indicating an inability to cover short-term obligations. The stock's 83.7% decline over the last year and -100% 5-year return reflect a total loss of investor confidence and a likely value trap scenario despite low P/S and P/B multiples.
Compare Another Pair
Related Comparisons
AEHL vs GWAV: Head-to-Head Comparison
This page compares Antelope Enterprise Holdings Limited (AEHL) and Greenwave Technology Solutions, Inc. (GWAV) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.